News By Wire

Food Safety Should Be Top Priority, Says Testing Expert

A leading specialist in food safety is urging the service industry to move testing higher up the agenda this year, after a string of reports about potentially life-threatening safety risks to consumers.

Experts at Eurofins Food & Water Testing (UK & Ireland) are encouraging the industry to make the testing regime even more thorough in a bid to improve consumer safety, after it was found that scores of allergen and pathogen-related product recalls were made in the UK last year alone.

“Food safety continues to be one of the biggest priorities for all businesses serving the sector, and for consumers who should be able to wholeheartedly trust in the products they buy,” explained Ali Aitchison, Food Safety Specialist at Eurofins.

“But as we’ve seen throughout the course of 2022, there are still many instances where product recalls have been made due to poor hygiene management, and cross-contamination with pathogens and contaminants, leading to many businesses – even some of the biggest chains – facing costly and potentially hugely damaging investigations.

“What makes it particularly challenging for the sector is that there is not one single piece of legislation stipulating which tests should be carried out. Businesses of course need to have rigorous processes in place to ensure they meet hygiene, food safety, and allergen management standards, but sadly so many still don’t have a proactive risk management approach.

“That means that many are doing what they think is right, but are often missing so many vital tests that could identify where improvements can be made, what the immediate risks are, and what they can do to reduce any such risks.”

According to Ali, some of the tests which are often overlooked include hygiene swabbing of equipment and machinery, microbiology food testing, and tests for establishing the presence of pathogens, allergens, and contaminants – all of which can be carried out as part of an overarching ‘suite’ of testing services.

“Not having thorough processes in place can pose a significant risk to consumers, who may develop severe food poisoning as a result of improper cleaning practices, or be inadvertently exposed to undeclared allergens – something which we know can have devastating consequences. For a business at fault, the impact could range from a small fine to complete closure, and for individuals, fines and even custodial sentences can be handed out.

“Ultimately, the gold standard for mitigating risk and leading the way is having a cohesive food safety management system in place which includes ensuring all vital and proactive tests are carried out on a regular basis – and not simply those that are most widely used across the industry. Being more thorough and leading the way in the suite of testing provided can protect consumers and raise the bar for the wider food service industry.”

For more information or to discuss the range of testing services available to those working in the food service industry, visit the website.

Press release information


Image File:


Area / Region:

Topics / Tags:

Notes to editors

For more information, please visit or contact: Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620 E-mail: [email protected] About Eurofins – the global leader in bio-analysis Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research services. Eurofins is also one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, BioPharma Contract Development and Manufacturing, advanced material sciences and in the support of clinical studies. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products. With 58,000 staff across a decentralised and entrepreneurial network of 900 laboratories in 54 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products. The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world. In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19. Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP). Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended. Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.

Media contact

Media contact name:

Zen Communications

Media contact business / organisation:

Zen Communications

Media contact telephone:


Media contact email:

All done!
Thank you for subscribing.

Email Subscription